Corporate News


Accuray supports its customers during COVID19

During these difficult and trying times of the COVID19 pandemic, Accuray has come together with its customers to provide innovative ways to assist them to be able to continue to care for their cancer patients.

As one initiative, Accuray’s Medical Affairs team is ready to provide customers with information regarding peer reviewed, published clinical literature. While its customers may be experiencing staff disruptions and shortages in qualified clinical staff, Accuray provides remote product training and clinical application’s support, a benefit of Accuray’s service agreements, to quickly train and educate new users.

In the US, Accuray also offers a remote physician-to-physician program which includes peer dialogue with knowledgeable clinicians who share experiences with Accuray systems’ hypofractionated and  ultra-hypofractionated treatment capabilities, as well as dose objectives and constraints, treatment margins, and any general “tips and tricks” that experienced users can provide.

Additionally, also available, is a recorded presentation hosted by a panel of physicians that provides an overview of the American Society for Radiation Oncology’s recommendation for treating cancer patients during the COVID-19 pandemic.  This panel of physicians also share measures taken by their departments to minimize infection risks and prioritize patient care. You can access this resource by clicking   HERE []

Continual mutual exchange of information is key during these times and Accuray has been in close contact with the ASTRO and ESTRO societies to work together and learn ways to assist their customers. ASTRO recommendations & information: []. ESTRO latest news for RTT departments:

For additional information on Accuray Covid update with offers to support their users:

[List of all articles]